Market cap
₹3 Cr
Revenue (TTM)
₹0 Cr
P/E Ratio
40.1
P/B Ratio
7.7
Div. Yield
0 %
| Transpact Ent | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
3 | 17,394 | 1,632 | 749 | 372 |
Revenue (₹ Cr) |
0 | 1,997 | 342 | 92 | 183 |
Net Profit (₹ Cr) |
0.01 | 307.01 | 55.72 | 4.71 | 12.72 |
Net Margin (%) |
-- | 14.56 | 16.04 | 5.06 | 6.90 |
RoE (%) |
2.01 | 10.63 | 25.55 | 4.92 | 10.39 |
Price to Earnings |
40.14 | 55.20 | 29.29 | 60.94 | 34.20 |
Price-To-Book |
7.73 | 5.47 | 3.34 | 5.36 | -- |
Income Statement (₹ Cr)
| Transpact Ent | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.08 | 1,669.83 | 313.14 | 92.43 | -- |
|
Total Income
|
0.08 | 1,758.96 | 325.22 | 93.00 | -- |
|
Total Expenditure
|
0.04 | 1,214.12 | 251.50 | 82.12 | -- |
|
EBITDA
|
0.04 | 455.71 | 61.64 | 10.31 | -- |
|
Depreciation
|
0.04 | 83.18 | 7.03 | 3.89 | -- |
|
EBIT
|
0.01 | 372.53 | 54.61 | 6.42 | -- |
|
Interest
|
0.00 | 14.32 | 14.97 | 0.41 | -- |
|
Other Income
|
-- | 89.13 | 12.08 | 0.57 | -- |
|
Exceptional Items
|
-- | -- | -16.97 | -- | -- |
|
Profit before Tax
|
0.00 | 452.52 | 34.74 | 6.59 | -- |
|
Provision for Tax
|
0.00 | 113.96 | 19.06 | 1.88 | -- |
|
Profit after Tax
|
0.01 | 338.56 | 15.68 | 4.71 | -- |
Liabilities (₹ Cr)
| Transpact Ent | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
0.45 | 2,765.66 | 189.95 | 98.04 | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.02 | 56.40 | 85.42 | 14.44 | -- |
|
Current Liabilities
|
0.23 | 457.71 | 179.14 | 18.62 | -- |
|
Total Liabilities
|
0.70 | 3,279.77 | 455.50 | 131.33 | -- |
Assets (₹ Cr)
| Transpact Ent | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.13 | 1,269.89 | 189.88 | 76.67 | -- |
|
Current Assets
|
0.57 | 2,009.87 | 264.64 | 54.44 | -- |
|
Total Assets
|
0.70 | 3,279.77 | 455.50 | 131.33 | -- |
|
Total Debt*
|
0.10 | 177.65 | 166.29 | 17.82 | -- |
|
Net Current Assets
|
0.34 | 1,552.17 | 85.50 | 35.81 | -- |
|
Contingent Liabilities
|
-- | 77.12 | 19.30 | 5.29 | -- |
Cashflow (₹ Cr)
| Transpact Ent | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.40 | 233.05 | 17.21 | 3.02 | -- |
|
Cash Flow from Investing Activities
|
-- | -1,187.18 | -77.47 | -14.74 | -- |
|
Cash from Financing Activities
|
-- | 950.51 | 53.18 | -0.60 | -- |
|
Net Cash Inflow / Outflow
|
-0.40 | -3.63 | -7.08 | -12.32 | -- |
Ratios
Profitability Ratios
| Transpact Ent | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
ROCE (%)
|
0.95 | 20.37 | 16.17 | 6.16 | -- |
|
ROE (%)
|
2.01 | 16.01 | 8.92 | 4.92 | -- |
|
ROA (%)
|
1.33 | 12.99 | 3.95 | 3.60 | -- |
|
EBIT Margin (%)
|
51.15 | 32.63 | 23.54 | 11.77 | -- |
|
Net Margin (%)
|
10.91 | 19.25 | 4.82 | 5.06 | -- |
|
Cash Profit Margin (%)
|
56.00 | 25.15 | 7.25 | 7.98 | -- |
Growth Ratios
| Transpact Ent | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 21.37 | 53.77 | -24.14 | -- |
|
EBIT Growth (%)
|
173.01 | 30.11 | 80.39 | -46.94 | -- |
|
Net Profit Growth (%)
|
109.90 | 31.09 | -27.54 | -58.34 | -- |
|
EPS Growth (%)
|
109.90 | 24.16 | -44.23 | -58.34 | -- |
|
Book Value Growth (%)
|
2.03 | 88.41 | 17.39 | 5.05 | -- |
Valuation Ratios
| Transpact Ent | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Price / Earnings
|
833.55 | 67.10 | 0.00 | 48.10 | -- |
|
Price / Book Value
|
16.62 | 8.22 | 0.00 | 2.31 | -- |
|
Dividend Yield (%)
|
0.00 | 0.16 | -- | 0.00 | -- |
|
EV/EBITDA
|
179.98 | 41.75 | 1.64 | 22.15 | -- |
|
Market Cap (₹ Cr)
|
7.50 | 22,718.23 | 0.00 | 226.53 | -- |
Solvency Ratios
| Transpact Ent | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.22 | 0.06 | 0.88 | 0.18 | -- |
|
Short term debt to equity ratio
|
0.22 | 0.06 | 0.29 | 0.00 | -- |
|
Current Ratio
|
2.49 | 4.39 | 1.48 | 2.92 | -- |
|
Quick Ratio
|
2.44 | 3.77 | 0.97 | 1.83 | -- |
|
Interest Coverage
|
6.25 | 32.59 | 3.32 | 17.26 | -- |
Operating Efficiency Ratios
| Transpact Ent | Poly Medicure | Q-Line Biotech | Saakshi Medtech | QMS Medical | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
117.82 | 20.94 | 26.38 | 23.68 | -- |
|
Asset Turnover
|
0.12 | 0.64 | 0.79 | 0.82 | -- |
|
Receivable days
|
218.34 | 67.43 | 63.55 | 66.41 | -- |
|
Inventory Days
|
55.30 | 55.13 | 113.91 | 71.27 | -- |
|
Payable days
|
-- | 74.14 | 143.30 | 54.28 | -- |
|
Cash Conversion Cycle
|
-- | 48.42 | 34.16 | 83.40 | -- |